Type of Malignancies in Patients With Clinical MEN-1 Versus Isolated Acromegaly
| . | Acropara . | Isolated Acromegaly . | P Value . |
|---|---|---|---|
| Personal history of any malignancy | 11/22 (50.0%) | 47/336 (14.0%)a | <0.001 b |
| Breast cancer | 3/13 (23.1%) | 4/185 (2.2%) | 0.007 b |
| Thyroid cancer | 3/22 (13.6%) | 9/335 (2.7%) | 0.031 |
| Skin cancer | 2/22 (9.1%) | 8/335 (2.4%) | 0.121 |
| Prostate cancer | 1/9 (11.1%) | 3/150 (2.0%) | 0.210 |
| Bladder cancer | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Glioblastoma | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Hematologic neoplasmc | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Neuroendocrine tumor | 1/22 (4.5%) | 0/335 (0%) | 0.062 |
| Renal cell cancer | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Colon cancer | 0/22 (0%) | 3/335 (0.9%) | 1 |
| . | Acropara . | Isolated Acromegaly . | P Value . |
|---|---|---|---|
| Personal history of any malignancy | 11/22 (50.0%) | 47/336 (14.0%)a | <0.001 b |
| Breast cancer | 3/13 (23.1%) | 4/185 (2.2%) | 0.007 b |
| Thyroid cancer | 3/22 (13.6%) | 9/335 (2.7%) | 0.031 |
| Skin cancer | 2/22 (9.1%) | 8/335 (2.4%) | 0.121 |
| Prostate cancer | 1/9 (11.1%) | 3/150 (2.0%) | 0.210 |
| Bladder cancer | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Glioblastoma | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Hematologic neoplasmc | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Neuroendocrine tumor | 1/22 (4.5%) | 0/335 (0%) | 0.062 |
| Renal cell cancer | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Colon cancer | 0/22 (0%) | 3/335 (0.9%) | 1 |
Acropara includes the group of patients who had acromegaly and primary hyperparathyroidism.
aIn the isolated acromegaly group, personal history of malignancy was available for 336 out of 338 patients. One female patient in the isolated acromegaly group had chemotherapy for a non-specified cancer. The other cancer types identified in the isolated acromegaly group included condrosarcoma, gastric sarcoma, testicular cancer and uterine cancers.
bSignificant after multivariate logistic analysis
cHematologic neoplasms include B-cell lymphoma, micosis fungoides, chronic lymphocytic leukemia and marginal cell lymphoma
Type of Malignancies in Patients With Clinical MEN-1 Versus Isolated Acromegaly
| . | Acropara . | Isolated Acromegaly . | P Value . |
|---|---|---|---|
| Personal history of any malignancy | 11/22 (50.0%) | 47/336 (14.0%)a | <0.001 b |
| Breast cancer | 3/13 (23.1%) | 4/185 (2.2%) | 0.007 b |
| Thyroid cancer | 3/22 (13.6%) | 9/335 (2.7%) | 0.031 |
| Skin cancer | 2/22 (9.1%) | 8/335 (2.4%) | 0.121 |
| Prostate cancer | 1/9 (11.1%) | 3/150 (2.0%) | 0.210 |
| Bladder cancer | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Glioblastoma | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Hematologic neoplasmc | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Neuroendocrine tumor | 1/22 (4.5%) | 0/335 (0%) | 0.062 |
| Renal cell cancer | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Colon cancer | 0/22 (0%) | 3/335 (0.9%) | 1 |
| . | Acropara . | Isolated Acromegaly . | P Value . |
|---|---|---|---|
| Personal history of any malignancy | 11/22 (50.0%) | 47/336 (14.0%)a | <0.001 b |
| Breast cancer | 3/13 (23.1%) | 4/185 (2.2%) | 0.007 b |
| Thyroid cancer | 3/22 (13.6%) | 9/335 (2.7%) | 0.031 |
| Skin cancer | 2/22 (9.1%) | 8/335 (2.4%) | 0.121 |
| Prostate cancer | 1/9 (11.1%) | 3/150 (2.0%) | 0.210 |
| Bladder cancer | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Glioblastoma | 1/22 (4.5%) | 2/335 (0.6%) | 0.174 |
| Hematologic neoplasmc | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Neuroendocrine tumor | 1/22 (4.5%) | 0/335 (0%) | 0.062 |
| Renal cell cancer | 1/22 (4.5%) | 4/335 (1.2%) | 0.274 |
| Colon cancer | 0/22 (0%) | 3/335 (0.9%) | 1 |
Acropara includes the group of patients who had acromegaly and primary hyperparathyroidism.
aIn the isolated acromegaly group, personal history of malignancy was available for 336 out of 338 patients. One female patient in the isolated acromegaly group had chemotherapy for a non-specified cancer. The other cancer types identified in the isolated acromegaly group included condrosarcoma, gastric sarcoma, testicular cancer and uterine cancers.
bSignificant after multivariate logistic analysis
cHematologic neoplasms include B-cell lymphoma, micosis fungoides, chronic lymphocytic leukemia and marginal cell lymphoma
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
